Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mizoribine Conversion for BKV Nephropathy Prevention in Kidney Transplant
NCT05293704Phase 4Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mizoribine in BK virus infection, sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoint: Number of Participants who had BKV-related nephropathy occurred at 12 months. Status: unknown.
02
Drugs
mizoribine
03
Conditions
BK virus infection
Beyond the preview
Go deeper on NCT05293704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293704.